© 2018 Smart + Strong. All Rights Reserved. Terms of use and Your privacy. Smart + Strong® is a registered trademark of CDM Publishing, LLC.

Advertisement

#Descovy

Gilead’s float in the Seattle LGBT pride parade, June 2017

Is Gilead’s Entire HIV Enterprise Built on a False Promise?

A new analysis finds that Gilead Sciences’ updated version of its key antiretroviral tenofovir may not actually offer any safety benefits.

Descovy Has Comparable Safety and Efficacy to Epzicom

In a randomized comparison trial, those who switched from Epzicom to Descovy had a comparable rate of HIV suppression.

U.S. Guidelines Panel Strongly Recommends Gilead’s HIV Regimen Biktarvy

The newly approved single-tablet regimen contains the integrase inhibitor bictegravir plus emtricitabine and tenofovir alafenamide.

Switching Off Ziagen Is Linked to Healthier Platelets in People With HIV

Ziagen is included in the combination-tablet regimens Triumeq and Trizivir and the two-drug combo tablet Epzicom.

Gilead Releases HIV Regimen Biktarvy, ViiV Sues for Patent Infringement

ViiV alleges that the bictegravir component of the tablet infringes on its own patent for Tivicay (dolutegravir).

FDA Approves Gilead’s Single-Tablet HIV Regimen Biktarvy

The once-daily regimen includes the integrase inhibitor bictegravir plus the contents of Descovy (emtricitabine/tenofovir alafenamide).

Gilead’s Updated Version of Tenofovir Performs Well Among Blacks With HIV

Compared with the older tenofovir, called TDF, the new one, TAF, suppressed the virus as well and offered bone, kidney and lipid benefits.

Gilead’s New Bictegravir-Based HIV Combo Pill Performs Well

A tablet containing bictegravir and the contents of Descovy suppressed HIV as well as boosted protease inhibitor regimens.

Janssen Seeks FDA Approval for Darunavir-Based Combo HIV Tablet

The combo tablet contains Janssen’s darunavir and Gilead Sciences cobicistat, emtricitabine and tenofovir alafenamide.

“Holy Grail” HIV Regimen Awaits FDA OK

The single-tablet HIV treatment regimen includes the experimental integrase inhibitor bictegravir and the contents of Descovy.
French AIDS ambassador Michèle Boccoz, executive director of UNAIDS Michel Sidibé, mayor of Paris Anne Hidalgo and Christine Kafando, a community health worker from Burkina Faso, speak at a press conference on the new 90-90-90 UNAIDS report.

International HIV Conference Reveals Exciting Progress in Global HIV Fight

Highlights from the research presented at the 9th International AIDS Society Conference on HIV Science in Paris.
The FDA approved Truvada for use as HIV prevention on July 16, 2012.

As PrEP Turns Five, the HIV Prevention Pill Is a Major Success

The science behind Truvada as pre-exposure prophylaxis reveals an awesome tool that is apparently already helping shrink U.S. HIV rates.

Gilead Files For FDA Approval of Integrase Inhibitor–Based HIV Regimen

The single-tablet regimen includes the experimental bictegravir plus the contents of Descovy (emtricitabine/tenofovir alafenamide).

Prevention: New PrEP Trial

New trial compares Descovy to Truvada.

Descovy

FDA OKs Gilead’s Descovy (Not for PrEP)

The U.S. Food and Drug Administration approved Gilead Sciences’ Descovy for the treatment of HIV in combination with other antiretrovirals.
Advertisement